Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments.
Healx has created the world’s most efficient AI platform for rare diseases which makes drug discovery faster, smarter and safer, and supports our team and partners in discovering and translating new treatments towards the clinic.
Healx was founded in 2014 by Tim Guilliams, David Brown, & Nick Sireau. The company is headquartered in Cambridge, Cambridgeshire, UK.
Healx's AI drug discovery platform leverages public and proprietary biomedical data and features the world’s leading knowledge graph for rare diseases.
Healx's Rare Treatment Accelerator is a collaboration programme for select rare disease patient groups and clinicians. Its aim is to combine each other’s knowledge, information and expertise, and to leverage the power of AI so that, together, they can discover new treatments and move them towards the clinic within 24 months.
Healx's has created Healnet, by leveraging public biomedical databases, scientific literature and proprietary curated data. Healnet can fill in critical knowledge gaps in rare diseases. They also cross-validate each other’s results and present preformed, data-driven hypotheses with unmatched speed and accuracy.
Healx is backed by Atomico, Intel Capital, Balderton Capital, Global Brain, btov Partners and others. The company raised $56M from a "Series B" financing on Oct 16, 2019. This bringgs Healx's total funding to $67.9M to date.